Insulet Corp. logo
PODDInsulet Corp.

Average EV/EBITDA Ratio

EV/EBITDA Ratio

The today ev/ebitda ratio is 18.99x as of Thursday, June 25, 2026, shown against its trailing averages.

PODD EV/EBITDA Ratio

PODD Average EV/EBITDA Ratio

PODD EV/EBITDA Ratio Averages

EV/EBITDA RATIO TODAY

18.99x

EV/EBITDA RATIO TTM

42.95x

EV/EBITDA RATIO 3Y

48.11x

EV/EBITDA RATIO 5Y

101.68x

EV/EBITDA RATIO 10Y

132.47x

EV/EBITDA RATIO 15Y

N/A

EV/EBITDA RATIO 20Y

N/A

About Insulet Corp.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Acton, MA
5,400 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Ashley A. McEvoy